EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A retrospective study of first‐line therapy and subsequent pyrotinib treatment in advanced lung adenocarcinoma with HER2 mutations

Li Wang iD, Yueran Wu, Zhixuan Ren, Xiangling Chu, Jianing Chen, Li Liu, Jing Zhao, Xin Yu, Mengqing Xie, Chunxia Su iD

Cancer Medicine · 2024

DOI: 10.1002/cam4.7335 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Li Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Shanghai Pulmonary Hospital and Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, People's R…. Hauptthemen laut MEDLINE: Lung Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Mutation, Acrylamides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Shenkang development research physician project, National Key R&D Program of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

HER2 is an infrequently mutated driver gene in non‐small cell lung cancer (NSCLC). At present, there has been no comprehensive large‐scale clinical study to establish the optimal first‐line treatment strategy for advanced lung adenocarcinoma (LUAD) with HER2‐Mutant. Besides that, the effectiveness and safety of pyrotinib, a pan‐HER inhibitor, in the context of NSCLC are still undergoing investigation. Materials and Methods In this study, we conducted a retrospective data collection of HER2‐Mutated advanced LUAD who received first‐line treatment and pyrotinib between May 2014 and June 2023. Patients treated with chemotherapy, chemotherapy + immune checkpoint inhibitors (ICIs), chemotherapy + bevacizumab and pyrotinib in first‐line treatment. Furthermore, we collected data on the efficacy and safety of pyrotinib in these patients after disease progression. The main endpoint of the study was progression‐free survival (PFS).

Results

In the final analysis, 89 patients were included in the first‐line cohort and 30 patients were included in the pyrotinib cohort. In the first‐line treatment cohort, chemotherapy + ICIs, chemotherapy + bevacizumab, and pyrotinib exhibited notable survival benefits compared to chemotherapy (median PFS: 9.87 vs. 7.77 vs. 7.10 vs. 5.40 months, p ‐value < 0.05). Furthermore, patients with a first‐line treatment PFS of less than 6 months may potentially benefit from subsequent treatment with pyrotinib (median PFS: 7.467 vs. 3.000, p ‐value = 0.0490).

Conclusions

In the first‐line treatment of HER2‐Mutant LUAD, regimens involving combinations like chemotherapy + ICIs, chemotherapy + bevacizumab, and pyrotinib may confer enhanced survival advantages compared to chemotherapy. Nevertheless, no significant distinctions were observed among these three treatment strategies, underscoring the imperative to identify biomarkers for the discerning selection of suitable therapeutic modalities. Moreover, patients with suboptimal response to first‐line treatment may potentially derive more benefit from pyrotinib.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsErb-b2 Receptor Tyrosine KinasesMutationAcrylamidesAdenocarcinoma of LungAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleRetrospective StudiesMaleMiddle AgedAgedProgression-Free SurvivalAdultAminoquinolinesImmune Checkpoint InhibitorsBevacizumabAged, 80 and over

Stichwörter der Autor:innen

HER2‐mutantefficacyfirst‐line treatmentlung adenocarcinomapyrotinib

Substanzen

Erb-b2 Receptor Tyrosine KinasesAcrylamidesAminoquinolinesImmune Checkpoint InhibitorsBevacizumabpyrotinibERBB2 protein, human

Autor:innen und Institutionen

  • Department of Medical Oncology, Shanghai Pulmonary Hospital and Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, People's Republic of China.
  • Department of Chronic Disease Prevention and Control, Jiujiang City Center for Disease Control and Prevention, Jiangxi, China.
  • Department of Radiation Oncology, Huadong Hospital Affiliated to Fudan University, Shanghai, People's Republic of China.

ORCID-Profile: Li Wang, Chunxia Su

Förderung

  • Shanghai Shenkang development research physician project
  • National Key R&D Program of China
  • National Natural Science Foundation of China
  • National Key Research and Development Program of China

Zitieren

APA

Wang, L., Wu, Y., Ren, Z., Chu, X., Chen, J., Liu, L., Zhao, J., Yu, X., Xie, M., & Su, C. (2024). A retrospective study of first‐line therapy and subsequent pyrotinib treatment in advanced lung adenocarcinoma with HER2 mutations. Cancer Medicine. https://doi.org/10.1002/cam4.7335

Vancouver

Wang L, Wu Y, Ren Z, Chu X, Chen J, Liu L, et al. A retrospective study of first‐line therapy and subsequent pyrotinib treatment in advanced lung adenocarcinoma with HER2 mutations. Cancer Medicine. 2024. doi:10.1002/cam4.7335

BibTeX
@article{Wang2024,
  author = {Wang, Li and Wu, Yueran and Ren, Zhixuan and Chu, Xiangling and Chen, Jianing and Liu, Li and Zhao, Jing and Yu, Xin and Xie, Mengqing and Su, Chunxia},
  title = {A retrospective study of first‐line therapy and subsequent pyrotinib treatment in advanced lung adenocarcinoma with HER2 mutations},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.7335}
}
Kostenlos starten →